Editorial
P latelet-rich thrombus generation at the vascular injury site is a primary underlying mechanism of ischemic event occurrence in patients with coronary artery disease. Thromboxane (Tx) A 2 and ADP act synergistically during platelet aggregation, and the ADP-P2Y 12 receptor interaction plays a central role in sustaining the activation of glycoprotein (GP) IIb/IIIa receptors by amplifying the response to agonists. On the basis of large-scale clinical trial data, therapy with clopidogrel (a P2Y 12 receptor blocker) plus aspirin (a cyclooxygenase [COX]-1 inhibitor)-dual antiplatelet therapy-has revolutionized the treatment of patients with high-risk coronary artery disease. 1 However, multiple pharmacodynamic studies primarily based on light transmittance aggregometry in patients undergoing stenting, uniformly revealed wide response variability and high platelet reactivity to ADP during clopidogrel therapy. 2 The latter observation subsequently was linked to single nucleotide polymorphisms in a major gene involved in the generation of clopidogrel active metabolite. Additional studies demonstrated an independent relation among high platelet reactivity, single nucleotide polymorphism carriage, and poststenting ischemic event occurrence. 3 Persistent treatment failure in large-scale clinical trials despite the ability of more potent and pharmacodynamically predictable P2Y 12 inhibitors, such as prasugrel and ticagrelor, to overcome high platelet reactivity has fueled the controversy surrounding mechanisms of clinical and laboratory resistance. 4
See accompanying article on page 2122
In the accompanying article, Hoefer et al 5 used confocal microscopy and flow cytometric imaging techniques in addition to light transmittance aggregometry to elucidate the potential role of uninhibited and inhibited (by aspirin or prasugrel active metabolite [PAM]) platelet subpopulations during in vitro platelet aggregation in static samples. The authors should be congratulated for their extensive and innovative investigations. First, they demonstrated that ≈30% uninhibited platelets of the total platelet populations can overcome aspirin-induced platelet inhibition. This observation is, in part, in line with earlier demonstrations of a nonlinear relationship between in vivo platelet COX-1 inhibition marked by urinary 2,3-dinor-TxB 2 excretion and ex vivo TxA 2 biosynthesis marked by serum TxB 2 ; the latter suggesting the role of TxA 2 produced by a small proportion of uninhibited platelets in sustaining arachidonic acid-induced aggregation. 6 After absorption, aspirin rapidly acetylates the platelet COX-1 enzyme in the prehepatic circulation. Aspirin is only transiently present in the plasma (up to ≈6 hours post administration). 7 Thereafter, newly formed platelets that enter the circulation are uninhibited and have the capacity to generate TxA 2 . The latter TXA 2 can bind to the TxA 2 receptor in aspirin-inhibited and aspirin-uninhibited platelets resulting in GP IIb/IIIa receptor activation and platelet aggregation. The latter mechanism may explain the homogenous distribution of both inhibited and uninhibited platelets observed after arachidonic acid-induced platelet aggregation in the current study (Figure [A] ). In addition, the latter phenomenon may also explain the ability of uninhibited platelets to overcome aspirininduced platelet inhibition. However, it is in contrast to an earlier observation of near absence of aspirin resistance assessed by light transmittance aggregometry in patients with high-risk coronary artery disease, a group expected to have high platelet turnover. 8 Nevertheless, in conditions of high platelet turnover, twice daily aspirin dosing or administration of extended release aspirin may improve 24-hour inhibition of platelet COX-1 and translate into positive antithrombotic effects.
Second, the authors report that ≈80% of uninhibited platelets of the total platelet population are required to fully overcome the inhibition of the P2Y 12 receptor by PAM with a linear relationship between the proportion of uninhibited platelets and the recovery of platelet response to ADP. Again, these observations are in line with an earlier definition of ≤10% inhibition of ADP-induced aggregation as clopidogrel resistance-an absence of a drug effect. 2 After stimulation by ADP, uninhibited platelets were observed to form a core of the platelet aggregate. ADP released by uninhibited platelets can activate only uninhibited platelets in a paracrine manner resulting in the amplification of platelet aggregation. Unlike the activation of aspirin-treated platelets by released TxA 2 , PAM-inhibited platelets cannot be activated by released ADP. Therefore, inhibited platelets were excluded from the core of the platelet aggregate (Figure [B] ). The mechanism(s) responsible for the recruitment of PAM-inhibited platelets to the uninhibited core deserves further studies that may help to unravel the mysteries behind antiplatelet resistance. Some limitations should be acknowledged when we consider the relevance of the in vitro study results to the in vivo situation. The in vitro experiments were conducted in static conditions that ignore the influence of arterial shear, which influences platelet function. Repeated platelet washings are Figure. Proposed mechanism of thrombus generation in the presence of uninhibited and inhibited platelets. A, Aspirin-inhibited and aspirin-uninhibited platelets: because aspirin inhibits the platelet cyclooxygenase-1 (COX-1) enzyme and not the upstream Thromboxane (Tx) A2 receptor, TxA2 generated by uninhibited platelets (green) activates the glycoprotein (GP) IIb/IIIa receptor by binding to the TxA2 receptor of aspirin-inhibited (red) platelets in a paracrine manner. This may explain the homogenous distribution of both inhibited and uninhibited platelets after AA-induced platelet aggregation in the current study. B, Prasugrel active metabolite-inhibited and prasugrel active metabolite-uninhibited platelets: After stimulation by adenosine diphosphate (ADP), uninhibited platelets form the core of the platelet aggregate. ADP released by uninhibited platelets (green) can activate only uninhibited platelets in a paracrine manner resulting in the amplification of platelet aggregation. Unlike the activation of aspirin-treated platelets by released TxA2, prasugrel active metabolite-treated platelets (red) cannot be activated by released ADP. Therefore, inhibited platelets were excluded from the core of the platelet aggregate.
